His‐Purkinje conduction system pacing: A systematic review and network meta‐analysis in bradycardia and conduction disorders. (25th October 2021)

• Record Type: Journal Article
• Authors: Qu, Qiang; Sun, Jin‐Yu; Zhang, Zhen‐Ye; Kan, Jun‐Yan; Wu, Li‐Da; Li, Feng; Wang, Ru‐Xing
• Is Part Of: Journal of cardiovascular electrophysiology. Volume 32:Number 12(2021)
• Page Start: 3245
• Page End: 3258
• Publication Date: 2021-10-25
• Subjects: bradycardia and conduction disorders -- His bundle pacing -- His‐Purkinje conduction system pacing -- left bundle branch pacing -- right ventricular pacing; Blood vessels -- Physiology -- Periodicals; Electrophysiology -- Periodicals; Heart -- Physiology -- Periodicals; 612.1
• DOI: 10.1111/jce.15269
• Languages: English
• ISSNs: 1045-3873

Abstract

Abstract: Background: His‐Purkinje conduction system pacing (HPCSP) has emerged as an effective alternative to overcome the limitations of right ventricular pacing (RVP) via physiological left ventricular activation, but there remains a paucity of comparative information for His bundle pacing (HBP) and left bundle branch pacing (LBBP). Methods: A Bayesian random‐effects network analysis was conducted to compare the relative effects of HBP, LBBP, and RVP in patients with bradycardia and conduction disorders. PubMed, Embase, Cochrane Library, and Web of Science were systematically searched from database inception until September 21, 2021. Results: Twenty‐eight studies involving 4160 patients were included in this meta‐analysis. LBBP significantly improved success rate, pacing threshold, pacing impedance, and R‐wave amplitude compared with HBP. LBBP also demonstrated a nonsignificant trend towards superior outcomes of lead complications, heart failure hospitalization, atrial fibrillation, and all‐cause death. However, HBP was associated with significantly shorter paced QRS duration relative to LBBP. Despite higher success rates, shorter procedure/fluoroscopy duration, and fewer lead complications, patients receiving RVP were more likely to experience reduced left ventricular ejection fraction, longer paced QRS duration, and higher rates of heart failure hospitalization than those receiving HPCSP. No statistical differences were observed in the remaining outcome measures. Conclusions: This network meta‐analysis demonstrates the efficacy and safety of HPCSP for the treatment of bradycardia and conduction disorders, with differences in pacing parameters, electrophysiology characteristics, and clinical outcomes between HBP and LBBP. Larger‐scale, long‐term comparative studies are warranted for further verification.